id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_povdtyhgjbhvzhhxlytu27olle	M. L. Maitland	Identification of a Variant in KDR Associated with Serum VEGFR2 and Pharmacodynamics of Pazopanib	2014.0	9	.pdf	application/pdf	7931	1084	53	association study of serum soluble vascular VEGFR2 concentrations [sVEGFR2], a pharmacodynamic biomarker for Experimental Design: We conducted a genome-wide association study (GWAS) of [sVEGFR2] in 736 healthy Old Order Amish Gene variants identified from the GWAS were genotyped serially in a cohort of 128 patients with advanced solid human cancer cohorts the change in [sVEGFR2] was associated To expedite discovery of gene variants that mark interindividual differences in response to VEGFR2 inhibitors, we performed a genome-wide association study (GWAS) of [sVEGFR2] enrolled, 121 had DNA and sVEGFR2 serum measurements available from baseline and after 4 weeks of pazopanib 500K SNP platform) and serum [sVEGFR2], 730 also had genotype data on the human cardiovascular disease risk focused that would be associated with serum [sVEGFR2] in the heterogeneous population of patients with cancer of European ancestry in KDR SNP Associated with Serum VEGFR2 and Pazopanib Pharmacodynamics KDR SNP Associated with Serum VEGFR2 and Pazopanib Pharmacodynamics	./cache/work_povdtyhgjbhvzhhxlytu27olle.pdf	./txt/work_povdtyhgjbhvzhhxlytu27olle.txt